GlassScriptPhysician profile
Mahmoud Kamel
NPI 1902036569
$1,290.42
in general payments reported to CMS, 2019-2025
18 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $35.86 · 2021: $58.11 · 2022: $184 · 2023: $326 · 2024: $296 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,012.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $226.84 | 2022-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $190.81 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $130.15 | 2023-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $116.73 | 2023-2025 | |
| Vantive US Healthcare LLC | $115.87 | 2025 | Renal - Acute |
| Horizon Therapeutics Plc | $93.38 | 2020-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $61.53 | 2024-2025 | Terlivaz |
| Novo Nordisk INC | $60.66 | 2022-2023 | Ozempic, Rybelsus |
| Apellis Pharmaceuticals, INC. | $50.94 | 2025 | Empaveli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.09 | 2023-2024 | Jardiance |
| Amgen INC. | $48.75 | 2022-2024 | Tavneos, Aranesp, Parsabiv |
| Lilly USA, LLC | $36.71 | 2024 | Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $32.04 | 2022-2023 | Benlysta |
| Aurinia Pharma U.S., INC. | $28.76 | 2025 | Lupkynis |
| Cycle Pharmaceuticals INC | $18.67 | 2025 | Venxxiva |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $16.95 | 2024 | Givlaari |
| Vifor Pharma, INC. | $12.54 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahmoud Kamel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.